Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28

Christoph A. Kahl, Jessica Bonnell, Suja Hiriyanna, Megan Fultz, Cassandra Nyberg-Hoffman, Ping Chen, C. Richter King, Jason G.D. Gall

    Research output: Contribution to journalArticle

    40 Scopus citations

    Abstract

    Adenovirus vaccine vectors derived from rare human serotypes have been shown to be less potent than serotype 5 (Ad5) at inducing immune responses to encoded antigens. To identify highly immunogenic adenovirus vectors, we assessed pro-inflammatory cytokine expression, binding to the CD46 receptor, and immunogenicity. Species D adenoviruses uniquely suppressed pro-inflammatory cytokines and induced high levels of type I interferon. Thus, it was unexpected that a vector derived from a representative serotype, Ad28, induced significantly higher transgene-specific T cell responses than an Ad35 vector. Prime-boost regimens with Ad28, Ad35, Ad14, or Ad5 significantly boosted T cell and antibody responses. The seroprevalence of Ad28 was confirmed to be <10% in the United States. Together, this shows that a rare human serotype-based vector can elicit strong immune responses, which was not predicted by . in vitro results.

    Original languageEnglish (US)
    Pages (from-to)5691-5702
    Number of pages12
    JournalVaccine
    Volume28
    Issue number35
    DOIs
    StatePublished - Aug 1 2010

      Fingerprint

    Keywords

    • Adenovirus
    • Human vaccine
    • Seroprevalence
    • Vector

    ASJC Scopus subject areas

    • Molecular Medicine
    • Immunology and Microbiology(all)
    • veterinary(all)
    • Public Health, Environmental and Occupational Health
    • Infectious Diseases

    Cite this

    Kahl, C. A., Bonnell, J., Hiriyanna, S., Fultz, M., Nyberg-Hoffman, C., Chen, P., King, C. R., & Gall, J. G. D. (2010). Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28. Vaccine, 28(35), 5691-5702. https://doi.org/10.1016/j.vaccine.2010.06.050